Product information and disease descriptionPlace of product in therapyApproaches to treatment
Current treatment options and standard of care
12 evidence topics · 12 sources
Zipalertinib (CLN-081)
EGFR exon 20 insertion-mutated non-small-cell lung cancer
- Manufacturer
- Taiho Oncology
- Regulatory submission
- NDA submitted February 2026
- Launch
- Not announced
- Last updated